New distributor Interlux Group to sell suPARnostic® in the Baltic countries
ViroGates has made a distribution agreement with Interlux Group based in Lithuania, that grants Interlux the rights to distribute ViroGates’ product range suPARnostic® in the Baltic region.
suPARnostic® TurbiLatex now CE-IVD approved on Siemens Healthineers ADVIA® XPT Chemical Diagnostics System
ViroGates announces that it has completed the development and regulatory approval (CE-IVD) of its suPARnostic® TurbiLatex product for the ADVIA® Chemistry XPT System from Siemens Healthineers.
Clinical Implementation of suPARnostic® TurbiLatex at Sygehus Lillebaelts two hospitals in Kolding and Vejle, Denmark
suPARnostic® will now be available for clinical decision making at Sygehus Lillebaelts two hospitals in Kolding and Vejle, Denmark. Both hospitals use the cobas system from Roche Diagnostics, an instrument line that was validated by ViroGates for use of the suPARnostic® TurbiLatex test earlier this year.
The Journal "suPAR News" No. 2, 2019 is out - read it here!
Read the Journal "suPAR News" No. 2, 2019 - with lots of interesting articles and interviews from around Europe!
Clinical Implementation of suPARnostic® TurbiLatex at University Hospital of Montpellier, France
suPARnostic® will now be available for clinical decision making in the University Hospital of Montpellier, France.
It will be the first hospital in the world to run suPARnostic® TurbiLatex at the Roche cobas 8000 system.
suPARnostic® launch on QIAGEN´s automated Lateral Flow aLF platform
ViroGates and QIAGEN announces a partnership to launch suPARnostic® Quick Triage on QIAGEN’s automated Lateral Flow (aLF) platform.
